Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 4.67% is in line with its 5-year average of 4.90%, near the low end of its 5-year range (3.07%–8.53%).
47.78% above its 12-month average of 3.16%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 2.67%.
RETURN ON ASSETS (ROA)
4.67%
RETURN ON ASSETS (ROA) AVG TTM
3.16%
RETURN ON ASSETS (ROA) AVG 3Y
4.61%
RETURN ON ASSETS (ROA) AVG 5Y
4.90%
RETURN ON ASSETS (ROA) AVG 10Y
6.73%
RETURN ON ASSETS (ROA) AVG 15Y
8.02%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+47.78%
CURRENT VS 3Y AVG
+1.19%
CURRENT VS 5Y AVG
-4.73%
CURRENT VS 10Y AVG
-30.62%
CURRENT VS 15Y AVG
-41.74%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
-9.14%
vs the sector median at left
AbbVie Inc.
Market Cap
$463.92B
Return on Assets (ROA)
4.67%
TTM Avg
3.16%
3Y Avg
4.61%
5Y Avg
4.90%
Market Cap
$358.00B
Return on Assets (ROA)
2.44%
TTM Avg
13.98%
3Y Avg
10.40%
5Y Avg
10.28%
Market Cap
$351.56B
Return on Assets (ROA)
12.78%
TTM Avg
10.46%
3Y Avg
11.93%
5Y Avg
13.23%
Market Cap
$340.79B
Return on Assets (ROA)
4.56%
TTM Avg
4.36%
3Y Avg
6.27%
5Y Avg
6.84%
Market Cap
$644.12B
Return on Assets (ROA)
10.46%
TTM Avg
10.63%
3Y Avg
12.96%
5Y Avg
11.95%
Market Cap
$252.62B
Return on Assets (ROA)
9.03%
TTM Avg
7.88%
3Y Avg
6.26%
5Y Avg
4.99%
Market Cap
$240.97B
Return on Assets (ROA)
6.17%
TTM Avg
6.31%
3Y Avg
6.46%
5Y Avg
7.20%
Market Cap
$203.12B
Return on Assets (ROA)
9.14%
TTM Avg
6.48%
3Y Avg
7.48%
5Y Avg
8.52%
Market Cap
$185.26B
Return on Assets (ROA)
19.90%
TTM Avg
20.27%
3Y Avg
22.54%
5Y Avg
48.60%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | $463.92B | 4.67% | 3.16% | 4.61% | 4.90% |
| Merck & Co., Inc. (MRK)vs › | $358.00B | 2.44% | 13.98% | 10.40% | 10.28% |
| Roche Holding AG (RHHBY)vs › | $351.56B | 12.78% | 10.46% | 11.93% | 13.23% |
| UnitedHealth Group Incorporated (UNH)vs › | $340.79B | 4.56% | 4.36% | 6.27% | 6.84% |
| Johnson & Johnson (JNJ)vs › | $644.12B | 10.46% | 10.63% | 12.96% | 11.95% |
| AstraZeneca PLC (AZN)vs › | $252.62B | 9.03% | 7.88% | 6.26% | 4.99% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $240.97B | 6.17% | 6.31% | 6.46% | 7.20% |
| Amgen Inc. (AMGN)vs › | $203.12B | 9.14% | 6.48% | 7.48% | 8.52% |
| Novo Nordisk A/S (NVO)vs › | $185.26B | 19.90% | 20.27% | 22.54% | 48.60% |
| Gilead Sciences, Inc. (GILD)vs › | $183.36B | -6.56% | 7.62% | 7.90% | 6.83% |
ROA
4.7%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 3.15% |
| 2024-12-31 | 3.17% |
| 2023-12-31 | 3.61% |
| 2022-12-31 | 8.53% |
| 2021-12-31 | 7.88% |
| 2020-12-31 | 3.07% |
| 2019-12-31 | 8.84% |
| 2018-12-31 | 9.58% |
| 2017-12-31 | 7.50% |
| 2016-12-31 | 9.01% |
| 2015-12-31 | 9.70% |
| 2014-12-31 | 6.45% |
| 2013-12-31 | 14.14% |
| 2012-12-31 | 19.53% |
| 2011-12-31 | 17.59% |
| 2010-12-31 | 19.77% |
| 2009-12-31 | 0.00% |
